* Sonnet Biotherapeutics Holdings Inc SONN.OQ SONN.O is
expected to show a fall in quarterly revenue when it reports
results on December 12 (estimated) for the period ending
September 30 2024
*
* LSEG's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of $5.52 per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $240.00, above its last
closing price of $1.98.
This summary was machine generated December 10 at 21:02 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)